Acetaminophen Mechanism of Action Acetaminophen is a centrally acting analgesic and antipyretic whose exact pharmacodynamics are not fully elucidated. The prevailing theory involves: Inhibition of cyclo‑oxygenase (COX) in the brain, with a preferential effect on COX‑2 or on a unique isoform, leading to ↓ prostaglandin synthesis and reduced pain and fever signaling. Modulation of the … Read more
Abilify Abilify (generic name aripiprazole) is a second‑generation antipsychotic widely used in psychiatric practice. It functions as a partial agonist at dopamine D₂ receptors and 5‑HT₁A receptors, while acting as an antagonist at 5‑HT₂A receptors. Its unique profile allows effective treatment across a spectrum of neuropsychiatric disorders with a relatively favorable side‑effect profile. Mechanism of … Read more
Abecma Abecma (idecabtagene vicleucel) is a bispecific chimeric antigen receptor (CAR) T‑cell therapy engineered to target B‑cell maturation antigen (BCMA) on malignant plasma cells. It is approved for adults with relapsed or refractory multiple myeloma (RRMM) after at least three prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug, and anti‑CD38 monoclonal antibody. — … Read more
Lorazepam Mechanism of Action Lorazepam is a benzodiazepine that binds to the benzodiazepine site on the GABA‑A receptor complex, acting as a positive allosteric modulator. This binding increases the frequency of chloride channel opening, hyperpolarizing neuronal membranes and reducing excitatory neurotransmission. The result is rapid anxiolytic, sedative‑hypnotic, anticonvulsant, and muscle‑relaxant activity. Pharmacokinetics Absorption: Oral bioavailability … Read more
Aripiprazole Aripiprazole is a second‑generation antipsychotic distinguished by its partial agonist activity at dopamine D₂/D₃ receptors and serotonin 5‑HT₁A receptors, with antagonism at 5‑HT₂A. It is used extensively for schizophrenia, bipolar disorder, and adjunctive depression. Mechanism of Action Partial dopamine agonism at D₂/D₃: acts as a functional antagonist in hyperdopaminergic states (schizophrenia, mania) and as … Read more
Generated Drug Card Nov 17, 2025 23:18 Mechanism of Action Novaptinib is a highly selective, oral inhibitor of phosphatidylinositol 3‑kinase alpha (PI3Kα). Binds the ATP‑binding pocket of the PI3Kα catalytic subunit with nanomolar affinity (IC₅₀ ≈ 2 nM). Blocks phosphorylation of downstream Akt and mTOR, thereby inhibiting tumor cell proliferation, survival, and angiogenesis. Minimal activity against PI3Kβ/γ/δ isoforms, … Read more
Agamree Mechanism of Action Agamree is a potent, orally‑available selective antagonist of the serotonin 5‑HT7 receptor. By competitively inhibiting 5‑HT7 at the postsynaptic site, it reduces cyclic‑AMP accumulation and downstream protein kinase A signaling. The blockade diminishes the serotonergic hyper‑activation that underlies visceral hypersensitivity in irritable bowel syndrome (IBS) and reduces colonic smooth‑muscle tone. In … Read more
Adderall Adderall is a prescription medication combining amphetamine salts (dextroamphetamine and levoamphetamine). It is primarily used as a central nervous system stimulant for the treatment of attention‑deficit/hyperactivity disorder (ADHD) and narcolepsy. The following drug card provides a concise yet comprehensive overview tailored for medical students and healthcare professionals. Mechanism of Action Central Sympathomimetic Stimulation: Blocks … Read more
Alfuzosin — Mechanism of Action Alfuzosin is a selective α1-adrenergic receptor antagonist. It preferentially blocks α1A‑ and α1B‑receptors in the smooth muscle of the prostate, bladder neck, and lower urinary tract. By inhibiting adrenergic stimulation, it reduces urethral and prostatic smooth‑muscle tone, thereby improving urine flow and decreasing bladder outlet obstruction. Its high receptor selectivity … Read more
Alendronate Alendronate is a first‑generation, nitrogen‑containing bisphosphonate used primarily to inhibit bone resorption and prevent fractures in osteoporotic and other high‑fracture‑risk patients. Mechanism of Action Alendronate binds to hydroxyapatite in bone and is selectively taken up by osteoclasts during bone‑resorption events. Inside osteoclasts, it inhibits farnesyl diphosphate synthase, blocking the mevalonate pathway and preventing prenylation of … Read more